Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

The Longitudinal Transcriptional Response to Neoadjuvant Chemotherapy with and without Bevacizumab in Breast Cancer.

Silwal-Pandit L, Nord S, von der Lippe Gythfeldt H, Møller EK, Fleischer T, Rødland E, Krohn M, Borgen E, Garred Ø, Olsen T, Vu P, Skjerven H, Fangberget A, Holmen MM, Schlitchting E, Wille E, Nordberg Stokke M, Moen Vollan HK, Kristensen V, Langerød A, Lundgren S, Wist E, Naume B, Lingjærde OC, Børresen-Dale AL, Engebraaten O.

Clin Cancer Res. 2017 Aug 15;23(16):4662-4670. doi: 10.1158/1078-0432.CCR-17-0160. Epub 2017 May 9.

2.

Associations between tumor vascularization assessed by in vivo DCE-MRI and the presence of disseminated tumor cells in bone marrow in breast cancer patients at the time of diagnosis.

Nilsen LB, Fangberget A, Geier OM, Engebraaten O, Borgen E, Olsen DR, Seierstad T.

J Magn Reson Imaging. 2014 Dec;40(6):1382-91. doi: 10.1002/jmri.24502. Epub 2014 Jan 27.

PMID:
24470360
3.

Quantitative analysis of diffusion-weighted magnetic resonance imaging in malignant breast lesions using different b value combinations.

Nilsen LB, Fangberget A, Geier O, Seierstad T.

Eur Radiol. 2013 Apr;23(4):1027-33. doi: 10.1007/s00330-012-2687-8. Epub 2012 Oct 31.

4.

Neoadjuvant chemotherapy in breast cancer-response evaluation and prediction of response to treatment using dynamic contrast-enhanced and diffusion-weighted MR imaging.

Fangberget A, Nilsen LB, Hole KH, Holmen MM, Engebraaten O, Naume B, Smith HJ, Olsen DR, Seierstad T.

Eur Radiol. 2011 Jun;21(6):1188-99. doi: 10.1007/s00330-010-2020-3. Epub 2010 Dec 3.

5.
6.

Integrin receptor imaging of breast cancer: a proof-of-concept study to evaluate 99mTc-NC100692.

Bach-Gansmo T, Danielsson R, Saracco A, Wilczek B, Bogsrud TV, Fangberget A, Tangerud A, Tobin D.

J Nucl Med. 2006 Sep;47(9):1434-9. Erratum in: J Nucl Med. 2007 Apr;48(4):567.

Supplemental Content

Loading ...
Support Center